Monopar Therapeutics Inc. (MNPR) DCF Valuation

Monopar Therapeutics Inc. (MNPR) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Monopar Therapeutics Inc. (MNPR) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Simplify Monopar Therapeutics Inc. (MNPR) valuation with this customizable DCF Calculator! Featuring real Monopar Therapeutics Inc. (MNPR) financials and adjustable forecast inputs, you can test scenarios and uncover Monopar Therapeutics Inc. (MNPR) fair value in minutes.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA .0 .0 .0 .0 .4 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation 4.3 6.5 9.1 10.5 8.8 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -4.3 -6.5 -9.1 -10.5 -8.4 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 13.2 16.7 20.3 13.1 7.3 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable .7 1.2 1.6 3.1 1.8 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -4.2 -6.4 -9.1 -10.5 -8.4 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF .8 .5 .4 1.6 -.9 -1.8 .0 .0 .0 .0
WACC, % 9.66 9.66 9.66 9.66 9.66 9.66 9.66 9.66 9.66 9.66
PV UFCF
SUM PV UFCF -1.6
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -2
Net Debt -7
Equity Value 6
Diluted Shares Outstanding, MM 15
Equity Value Per Share 0.39

What You Will Get

  • Real MNPR Financial Data: Pre-filled with Monopar Therapeutics Inc.’s historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See Monopar Therapeutics Inc.’s intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Monopar Therapeutics Inc. (MNPR).
  • WACC Calculator: Comes with a pre-built Weighted Average Cost of Capital sheet that allows for customizable inputs.
  • Adjustable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates to fit your analysis.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for Monopar Therapeutics Inc. (MNPR).
  • Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review Monopar Therapeutics Inc.'s pre-filled financial data and forecasts.
  3. Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Watch the DCF model update instantly as you tweak assumptions.
  5. Step 5: Analyze the outputs and use the results for investment decisions.

Why Choose This Calculator for Monopar Therapeutics Inc. (MNPR)?

  • User-Friendly Interface: Perfectly crafted for both novices and seasoned professionals.
  • Customizable Inputs: Effortlessly adjust parameters to suit your financial analysis.
  • Real-Time Valuation: Instantly view changes in Monopar’s valuation as you modify inputs.
  • Preloaded Data: Comes with Monopar’s actual financial statistics for swift evaluations.
  • Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.

Who Should Use Monopar Therapeutics Inc. (MNPR)?

  • Investors: Gain insights into innovative therapeutics with a focus on oncology and rare diseases.
  • Pharmaceutical Analysts: Streamline evaluations with access to comprehensive clinical trial data and market analysis.
  • Healthcare Consultants: Easily tailor reports and presentations to showcase Monopar's strategic initiatives.
  • Biotech Enthusiasts: Enhance your knowledge of drug development processes and the biotech landscape.
  • Educators and Students: Utilize it as a resource for case studies in pharmaceutical and biotechnology courses.

What the Template Contains

  • Pre-Filled DCF Model: Monopar Therapeutics Inc.’s (MNPR) financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital specific to Monopar Therapeutics Inc. (MNPR).
  • Financial Ratios: Evaluate Monopar Therapeutics Inc.’s (MNPR) profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios for Monopar Therapeutics Inc. (MNPR).
  • Financial Statements: Annual and quarterly reports for Monopar Therapeutics Inc. (MNPR) to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results for Monopar Therapeutics Inc. (MNPR).

No products were found matching.